Brain Tumour Group,Breast Cancer Group,Head and Neck Cancer Group,Lung Cancer Group,News,Radiation Oncology Group
EORTC, CTI, and IRROG collaboration opens new opportunities in Ireland
12 Dec 2022
In June 2022, EORTC and Cancer Trials Ireland (CTI) started discussions on the potential opening of the IRL network to a closer collaboration with EORTC.
Cancer Trials Ireland is an all-Ireland hub for cancer trials and as such the leading cancer research organization for Ireland. Their network represents multidisciplinarity, including Translational research scientists, data managers, and pharmacists, and covers about 98% of cancer-treating specialists in Ireland. With those similarities to EORTC, a closer collaboration between both organizations seems a logical next step.
CTI is organized in DSSG, disease-specific sub-groups, which match the structure of EORTC. Since June 2022 connections have been made in 4 major disciplines, Breast, Head & Neck, Brain and Lung, being the groups covering the largest incidence of cancer in Ireland. Together with the approach of CTI, the newly created IRROG (Irish Research Radiation Oncology Group) searched for closer collaboration with EORTC. The IRROG network covers the radiation oncology sites in IRL and focuses, likewise the EORTC Radiation Oncology Scientific Council (ROSC), on setting strategies in radiation oncology.
IRROG is supported by CTI for the set-up and coordination of its research portfolio. EORTC and CTI are working on a memorandum of understanding that will cover the intention for keeping the mutual network informed on planned, ongoing research that could benefit from a larger contribution. All members of CTI can become members of EORTC for allowing direct communication and acknowledgement of CTI membership. As such the IRL network will have a direct connection with the EORTC for new projects and research opportunities.
Related News
Full validation of the EORTC CAT Core
6 Jun 2023
SISAQOL-IMI: Setting standards for the use of patient-reported outcome data in cancer trials
1 Jun 2023
Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types
30 May 2023
Publication of 2022 EORTC Annual Report
25 May 2023
EORTC is supporting Clinical Trials Day on 20th May
19 May 2023
Studying long-term survivors of glioblastoma may pave the way to better treatment
10 May 2023
Three new EORTC clinical trials funded by the EU
24 Apr 2023
Important new results from EORTC to be presented at ESTRO 2023
14 Apr 2023
EORTC QLG proudly collaborates on the EUonQoL project
21 Mar 2023
HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer
22 Feb 2023